Scarica l'app Stockscreener
1.55
0.64%
-0.01
Pre-mercato:
1.53
-0.02
-1.29%
Precedente Chiudi:
$1.56
Aprire:
$1.61
Volume 24 ore:
148.48K
Relative Volume:
0.08
Capitalizzazione di mercato:
$3.54M
Reddito:
$644.60K
Utile/perdita netta:
$-9.87M
Rapporto P/E:
-0.00185
EPS:
-837.9618
Flusso di cassa netto:
$-9.02M
1 W Prestazione:
+8.39%
1M Prestazione:
-2.52%
6M Prestazione:
-75.44%
1 anno Prestazione:
-91.45%
Intervallo 1D:
$1.52
$1.65
Intervallo di 1 settimana:
$1.2396
$1.65
Portata 52W:
$1.14
$74.00
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Company Profile
Nome
Biodexa Pharmaceuticals Plc Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta BDRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BDRX
Biodexa Pharmaceuticals Plc Adr
|
1.55 | 3.54M | 644.60K | -9.87M | -9.02M | -837.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-02-08 | Iniziato | Ladenburg Thalmann | Buy |
Biodexa Pharmaceuticals Plc Adr Borsa (BDRX) Ultime notizie
What Makes Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) a New Buy Stock - MSN
Biodexa Pharmaceuticals advances FAP treatment trial By Investing.com - Investing.com South Africa
Biodexa Pharmaceuticals advances FAP treatment trial - Investing.com India
Biodexa gets FDA nod for Phase 3 eRapa study in FAP - Investing.com India
BDRXBiodexa Pharmaceuticals plc Latest Stock News & Market Updates - StockTitan
Why Plus Therapeutics, Inc. (PSTV) Soared on Thursday - Yahoo Finance
Biodexa selects Precision as CRO for eRapa Phase 3 study in Europe - Investing.com
Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status - Barchart
Biodexa Pharmaceuticals Plc ADR [BDRX] Is Currently 31.94 above its 200 Period Moving Avg: What Does This Mean? - The DBT News
why Teva- Pharmaceutical Industries Ltd. ADR [TEVA] is a Good Choice for Investors After New Price Target of $24.71 - The DBT News
Palantir Technologies Inc [PLTR] Is Currently -0.39 below its 200 Period Moving Avg: What Does This Mean? - The DBT News
Biodexa Pharmaceuticals Plc ADR (BDRX) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
Hesai Group ADR (HSAI) Shares Up Despite Recent Market Volatility - The News Heater
Biodexa Pharmaceuticals Plc ADR (BDRX) vs. Its Peers: A Comparison - The News Heater
Omega Therapeutics Inc (OMGA) Stock: A SWOT Analysis - The News Heater
AES Corp (AES) Shares Down Despite Recent Market Volatility - The News Heater
Altus Power Inc (AMPS) vs. Its Peers: A Comparison - The News Heater
Skechers (SKX) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Is Argenx (ARGX) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Are Medical Stocks Lagging Argenx (ARGX) This Year? - Yahoo Finance
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Moves to Buy: Rationale Behind the Upgrade - MSN
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading - MSN
Biodexa Pharmaceuticals Plc ADR (BDRX): A New Perspective - Stocks Register
Result of General Meeting - Yahoo Finance
Gaining Momentum, Biodexa Is Advancing Two Recent Acquisitions Through The Clinic - Barchart
Biodexa Pharmaceuticals regains Nasdaq compliance - Investing.com
Notice of General Meeting - StockTitan
Biodexa Pharmaceuticals Submits SEC Filing with Auditors’ Nod - TipRanks
BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
Biodexa reports promising glioblastoma trial results - Investing.com
Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer - StockTitan
Biodexa Pharmaceuticals Secures Nasdaq Compliance Extension - TipRanks
Biodexa Pharmaceuticals granted extension to regain compliance with Nasdaq - TipRanks
Biodexa Announces Successful Appeal of Nasdaq Delisting - StockTitan
Biodexa secures Nasdaq listing extension - Investing.com
Biodexa reports survival rates in glioblastoma study - Investing.com
Interim results for the six months ended June 30, 2024 - StockTitan
ADR Ratio Change - GlobeNewswire
Biodexa secures full access to cancer research grant - Investing.com
Receipt of Nasdaq Delisting DeterminationPlans to Appeal - StockTitan
Biodexa Pharmaceuticals sets $5 million offering - Investing.com
BDRX Stock Price and Chart — NASDAQ:BDRX - TradingView
Biodexa’s Diabetes Drug Enters Phase 2a Studies - TipRanks
Biodexa Announces Additional Positive Results Of Phase 2 Trial Of eRapa in Treatment Of Precancerous Polyps in the GI TractNow 12-Month Data - StockTitan
Biodexa’s eRapa Shows Promise in FAP Treatment - TipRanks
PRFX Stock Quote Price and Forecast - CNN
symbol__ Stock Quote Price and Forecast - CNN
Biodexa Pharmaceuticals will rise 8,000% at the open - Dhaka Tribune
Biodexa Pharma (BDRX) Stock Rallied 27% on Investor Interest - AskTraders.com
Why Virgin Galactic Are Trading Lower By Around 18%; Here Are 20 Stocks Moving Premarket - markets.businessinsider.com
Biodexa Pharmaceuticals (BDRX) Stock Price, News & Analysis - MarketBeat
Biodexa Pharmaceuticals Plc Adr Azioni (BDRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.24%
36.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):